[Pharmacological treatment of overactive bladder: the potential of anticholinergic therapy]

The management of overactive bladder (OAB) involves drugs from several pharmacological classes, among which anticholinergic agents occupy an important place. The choice of therapy should be strictly individualized, taking into account not only the expected efficacy but also potential drug interactions, age-related pharmacokinetic and pharmacodynamic changes, comorbidities, the overall anticholinergic burden, and the risk of adverse effects. Trospium chloride (Spasmex) is considered the drug of choice for patients with OAB. Its pharmacological properties ensure both clinical efficacy and good tolerability, along with proven cognitive safety. Trospium chloride does not cross the blood-brain barrier and therefore does not cause central nervous system adverse effects. Another advantage of trospium chloride is the flexible dosing regimen, which allows for individualized dose titration according to patient response and tolerability.